Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$13.84
0.040.29%
Pre-Market: 6:30 AM EDT
Comments
Loading...
Arrowhead Pharma Analyst Ratings and Price Targets | NASDAQ:ARWR | Benzinga
Arrowhead Pharmaceuticals Inc has a consensus price target of $47.53 based on the ratings of 20 analysts. The high is $80 issued by HC Wainwright & Co. on February 12, 2025. The low is $24 issued by Bernstein on November 29, 2024. The 3 most-recent analyst ratings were released by B. Riley Securities, HC Wainwright & Co., and RBC Capital on February 14, 2025, February 12, 2025, and February 11, 2025, respectively. With an average price target of $53.33 between B. Riley Securities, HC Wainwright & Co., and RBC Capital, there's an implied 285.36% upside for Arrowhead Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B. Riley Securities
HC Wainwright & Co.
RBC Capital
Chardan Capital
Bernstein
1calculated from analyst ratings
Analyst Ratings for Arrowhead Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/14/2025 | Buy Now | 174.57% | B. Riley Securities | Mayank Mamtani72% | $51 → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 478.03% | HC Wainwright & Co. | Patrick Trucchio48% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 203.47% | RBC Capital | Luca Issi43% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 02/11/2025 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
| 01/23/2025 | Buy Now | 478.03% | HC Wainwright & Co. | Patrick Trucchio48% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | 478.03% | HC Wainwright & Co. | Patrick Trucchio48% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
| 12/03/2024 | Buy Now | 478.03% | HC Wainwright & Co. | Patrick Trucchio48% | $60 → $80 | Maintains | Buy | Get Alert |
| 11/29/2024 | Buy Now | 73.41% | Bernstein | William Pickering45% | $27 → $24 | Maintains | Market Perform | Get Alert |
| 11/27/2024 | Buy Now | 225.14% | Piper Sandler | Edward Tenthoff52% | $62 → $45 | Maintains | Overweight | Get Alert |
| 11/27/2024 | Buy Now | 87.86% | Citigroup | Shawn Egan51% | $27 → $26 | Maintains | Neutral | Get Alert |
| 11/27/2024 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
| 11/20/2024 | Buy Now | 333.53% | HC Wainwright & Co. | Patrick Trucchio48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | 333.53% | HC Wainwright & Co. | Patrick Trucchio48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/08/2024 | Buy Now | 347.98% | Piper Sandler | Edward Tenthoff52% | $62 → $62 | Reiterates | Overweight → Overweight | Get Alert |
| 09/26/2024 | Buy Now | 203.47% | RBC Capital | Luca Issi43% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer55% | — | Reiterates | → Overweight | Get Alert |
| 09/05/2024 | Buy Now | 333.53% | HC Wainwright & Co. | Patrick Trucchio48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 333.53% | HC Wainwright & Co. | Patrick Trucchio48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 297.4% | B. Riley Securities | Mayank Mamtani72% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 07/23/2024 | Buy Now | 333.53% | HC Wainwright & Co. | Patrick Trucchio48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/17/2024 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
| 07/05/2024 | Buy Now | 333.53% | HC Wainwright & Co. | Patrick Trucchio48% | $90 → $60 | Maintains | Buy | Get Alert |
| 06/26/2024 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Alethia Young76% | — | Reiterates | → Overweight | Get Alert |
| 06/11/2024 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 123.99% | Goldman Sachs | Andrea Tan42% | → $31 | Initiates | → Neutral | Get Alert |
| 06/03/2024 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 95.09% | Morgan Stanley | Michael Ulz57% | $36 → $27 | Maintains | Equal-Weight | Get Alert |
| 05/10/2024 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
| 02/08/2024 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | Buy Now | 261.27% | RBC Capital | Luca Issi43% | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 02/07/2024 | Buy Now | 160.12% | Morgan Stanley | Michael Ulz57% | $34 → $36 | Maintains | Equal-Weight | Get Alert |
| 02/07/2024 | Buy Now | 145.66% | Citigroup | Shawn Egan51% | $33 → $34 | Maintains | Neutral | Get Alert |
| 01/16/2024 | Buy Now | 261.27% | RBC Capital | Luca Issi43% | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 01/02/2024 | Buy Now | 167.34% | B of A Securities | Jason Gerberry62% | $29 → $37 | Maintains | Buy | Get Alert |
| 12/04/2023 | Buy Now | 109.54% | B of A Securities | Jason Gerberry62% | → $29 | Initiates | → Buy | Get Alert |
| 11/30/2023 | Buy Now | 167.34% | Morgan Stanley | Michael Ulz57% | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 11/30/2023 | Buy Now | 261.27% | RBC Capital | Luca Issi43% | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 09/19/2023 | Buy Now | 138.44% | Citigroup | Shawn Egan51% | → $33 | Initiates | → Neutral | Get Alert |
| 08/09/2023 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 239.6% | Cantor Fitzgerald | Alethia Young76% | $79 → $47 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 333.53% | RBC Capital | Luca Issi43% | → $60 | Reiterates | Outperform → Outperform | Get Alert |
| 07/21/2023 | Buy Now | — | TD Cowen | Brendan Smith36% | — | Initiates | → Outperform | Get Alert |
| 07/20/2023 | Buy Now | 297.4% | B. Riley Securities | Mayank Mamtani72% | → $55 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 326.3% | Piper Sandler | Edward Tenthoff52% | $52 → $59 | Maintains | Overweight | Get Alert |
| 06/02/2023 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 189.02% | SVB Leerink | Mani Foroohar46% | → $40 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/03/2023 | Buy Now | 333.53% | RBC Capital | Luca Issi43% | → $60 | Reiterates | → Outperform | Get Alert |
| 05/03/2023 | Buy Now | 427.46% | Goldman Sachs | Madhu Kumar72% | $65 → $73 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 189.02% | Morgan Stanley | Michael Ulz57% | $37 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/26/2023 | Buy Now | 478.03% | SMBC Nikko | David Hoang43% | → $80 | Initiates | → Outperform | Get Alert |
| 04/12/2023 | Buy Now | 152.89% | SVB Securities | Mani Foroohar46% | $21 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 03/21/2023 | Buy Now | 95.09% | Bernstein | William Pickering45% | → $27 | Initiates | → Market Perform | Get Alert |
| 02/10/2023 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | → $90 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | 333.53% | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | 297.4% | B. Riley Securities | Mayank Mamtani72% | $59 → $55 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | 456.36% | RBC Capital | Luca Issi43% | $83 → $77 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | 319.08% | Baird | Joel Beatty69% | $60 → $58 | Maintains | Outperform | Get Alert |
| 02/07/2023 | Buy Now | 275.72% | Piper Sandler | Edward Tenthoff52% | $55 → $52 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 550.29% | HC Wainwright & Co. | Patrick Trucchio48% | $110 → $90 | Maintains | Buy | Get Alert |
| 11/30/2022 | Buy Now | 326.3% | B. Riley Securities | Mayank Mamtani72% | $65 → $59 | Maintains | Buy | Get Alert |
| 11/29/2022 | Buy Now | 441.91% | Jefferies | Maury Raycroft31% | $92 → $75 | Maintains | Buy | Get Alert |
| 11/29/2022 | Buy Now | 167.34% | Morgan Stanley | Andrew Galler32% | $41 → $37 | Maintains | Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | 123.99% | SVB Leerink | Mani Foroohar46% | $33 → $31 | Maintains | Market Perform | Get Alert |
| 11/10/2022 | Buy Now | 362.43% | Piper Sandler | Edward Tenthoff52% | $72 → $64 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | 138.44% | SVB Leerink | Mani Foroohar46% | $32 → $33 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 196.24% | Morgan Stanley | Andrew Galler32% | → $41 | Initiates | → Equal-Weight | Get Alert |
| 08/08/2022 | Buy Now | 369.65% | Goldman Sachs | Madhu Kumar72% | $58 → $65 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 694.8% | HC Wainwright & Co. | Patrick Trucchio48% | $100 → $110 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 376.88% | Goldman Sachs | Madhu Kumar72% | $90 → $66 | Maintains | Buy | Get Alert |
| 05/11/2022 | Buy Now | 478.03% | Chardan Capital | Keay Nakae58% | $94 → $80 | Maintains | Buy | Get Alert |
| 05/11/2022 | Buy Now | 420.23% | Piper Sandler | Edward Tenthoff52% | $89 → $72 | Maintains | Overweight | Get Alert |
| 05/11/2022 | Buy Now | 333.53% | Baird | Joel Beatty69% | $71 → $60 | Upgrade | Neutral → Outperform | Get Alert |
| 05/11/2022 | Buy Now | 152.89% | SVB Leerink | Mani Foroohar46% | $36 → $35 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Arrowhead Pharma (ARWR) stock?
The latest price target for Arrowhead Pharma (NASDAQ:ARWR) was reported by B. Riley Securities on February 14, 2025. The analyst firm set a price target for $38.00 expecting ARWR to rise to within 12 months (a possible 174.57% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arrowhead Pharma (ARWR)?
The latest analyst rating for Arrowhead Pharma (NASDAQ:ARWR) was provided by B. Riley Securities, and Arrowhead Pharma reiterated their buy rating.
When was the last upgrade for Arrowhead Pharma (ARWR)?
The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 12, 2023 when SVB Securities raised their price target to $35. SVB Securities previously had a market perform for Arrowhead Pharmaceuticals Inc.
When was the last downgrade for Arrowhead Pharma (ARWR)?
The last downgrade for Arrowhead Pharmaceuticals Inc happened on May 12, 2023 when SVB Leerink changed their price target from N/A to $40 for Arrowhead Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Arrowhead Pharma (ARWR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.
Is the Analyst Rating Arrowhead Pharma (ARWR) correct?
While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a reiterated with a price target of $51.00 to $38.00. The current price Arrowhead Pharma (ARWR) is trading at is $13.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.